Hack Andrew A. F. (CIK 0001657434)

Latest company ownership

Shares held
2,915,000
Last filed at
May 19, 2023
Confidence Score
50.0
2025Q4
Confidence Score History
2020Q2 2025Q4
NUVL - Nuvalent, Inc.
Role: Director
Shares held
2,697,267
Last filed at
Mar 29, 2024
Confidence Score
49.9
2025Q4
Confidence Score History
2021Q3 2025Q4
Shares held
1,982,469
Last filed at
Nov 3, 2020
Confidence Score
50.0
2025Q4
Confidence Score History
2020Q4 2025Q4
Shares held
55,000
Last filed at
Jun 12, 2024
Confidence Score
50.0
2025Q4
Confidence Score History
2020Q2 2025Q4
Shares held
6,895
Last filed at
Feb 6, 2019
Confidence Score
50.0
2025Q4
Confidence Score History
2017Q1 2025Q4

Recent buy/sell transactions

Exec date Filing date Company Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Dec 11, 2024 Dec 13, 2024 Nuvalent, Inc. Director Sell 15.0 -1,250,000 -46.30% ✗ $110M
Mar 27, 2024 Mar 29, 2024 Nuvalent, Inc. Director Sell 15.0 -880,000 -24.60% ✗ $64M
Aug 8, 2023 Aug 10, 2023 DYNAVAX TECHNOLOGIES CORP Director Sell 15.0 -1,500,000 -61.84% ✗ $21.6M
Jun 14, 2023 Jun 16, 2023 DYNAVAX TECHNOLOGIES CORP Director Sell 16.3 -500,000 -17.09% ✗ $6.3M
May 18, 2023 May 19, 2023 DYNAVAX TECHNOLOGIES CORP Director Sell 15.0 -1,000,000 -25.54% ✗ $10.6M
Dec 6, 2022 Dec 8, 2022 DYNAVAX TECHNOLOGIES CORP Director Sell 15.0 -1,500,000 -27.70% ✗ $17.4M
Nov 3, 2022 Nov 3, 2022 Nuvalent, Inc. Director Buy 92.5 +149,253 4.35% ✗ $5M
Aug 15, 2022 Aug 17, 2022 DYNAVAX TECHNOLOGIES CORP Director Sell 15.0 -3,000,000 -35.65% ✗ $44M
May 31, 2022 Jun 2, 2022 Mersana Therapeutics, Inc. Director Buy 85.0 +95,519 1.11% ✗ $312K
May 24, 2022 May 26, 2022 Mersana Therapeutics, Inc. Director Buy 90.0 +265,155 3.19% ✗ $854.2K
May 19, 2022 May 23, 2022 Mersana Therapeutics, Inc. Director Buy 90.0 +215,599 2.67% ✗ $746.4K
May 16, 2022 May 18, 2022 Mersana Therapeutics, Inc. Director Buy 92.5 +350,000 4.52% ✗ $1.1M
Apr 13, 2022 Apr 14, 2022 Mersana Therapeutics, Inc. Director Buy 95.0 +617,284 8.67% ✗ $2.5M
Apr 12, 2022 Apr 13, 2022 Mersana Therapeutics, Inc. Director Buy 95.0 +598,086 9.17% ✗ $2.5M
Feb 7, 2022 Feb 8, 2022 Mersana Therapeutics, Inc. Director Buy 100.0 +1,136,363 21.10% ✗ $5M
Dec 30, 2021 Jan 4, 2022 Mersana Therapeutics, Inc. Director Buy 100.0 +815,000 17.83% ✗ $5M
Dec 29, 2021 Jan 3, 2022 Mersana Therapeutics, Inc. Director Buy 100.0 +875,000 23.68% ✗ $5M
Aug 27, 2021 Aug 27, 2021 DYNAVAX TECHNOLOGIES CORP Director Sell 15.0 -2,000,000 -19.20% ✗ $32.4M
Aug 9, 2021 Aug 11, 2021 DYNAVAX TECHNOLOGIES CORP Director Sell 15.0 -2,250,000 -20.88% ✗ $24.3M
Aug 2, 2021 Aug 4, 2021 Nuvalent, Inc. Director Buy 100.0 +735,000 27.29% ✗ $12.5M
Jan 8, 2021 Jan 12, 2021 Mersana Therapeutics, Inc. Director Buy 95.0 +250,000 7.26% ✗ $4.6M
Nov 3, 2020 Nov 3, 2020 Atea Pharmaceuticals, Inc. Director Buy 93.8 +250,000 4.66% ✗ $6M
May 27, 2020 May 28, 2020 DYNAVAX TECHNOLOGIES CORP Director Buy 100.0 +1,000,000 13.29% ✗ $5M
Apr 7, 2020 Apr 9, 2020 Mersana Therapeutics, Inc. Director Buy 100.0 +3,445,667 100.00% ✗ $20.6M
Feb 4, 2019 Feb 6, 2019 Editas Medicine, Inc. CFO Sell 10.0 -6,895 -100.00% ✓ $147.5K
Jan 4, 2019 Jan 8, 2019 Editas Medicine, Inc. CFO Sell 10.0 -7,000 -100.00% ✓ $157.4K
Nov 23, 2018 Nov 27, 2018 Editas Medicine, Inc. CFO Sell 10.0 -5,284 -100.00% ✓ $148.7K
Oct 26, 2018 Oct 30, 2018 Editas Medicine, Inc. CFO Sell 10.0 -6,000 -100.00% ✓ $154.2K
Sep 28, 2018 Oct 2, 2018 Editas Medicine, Inc. CFO Sell 7.5 -8,000 -100.00% ✓ $256.6K
Aug 31, 2018 Sep 5, 2018 Editas Medicine, Inc. CFO Sell 7.5 -10,000 -100.00% ✓ $322.3K
Jun 1, 2018 Jun 5, 2018 Editas Medicine, Inc. CFO Sell 7.5 -10,000 -100.00% ✓ $386.3K
Mar 16, 2018 Mar 20, 2018 Editas Medicine, Inc. CFO Sell 5.0 -40,000 -100.00% ✓ $1.5M
Feb 14, 2018 Feb 16, 2018 Editas Medicine, Inc. CFO Sell 7.5 -18,000 -100.00% ✓ $615.8K
Dec 15, 2017 Dec 19, 2017 Editas Medicine, Inc. CFO Sell 7.5 -14,649 -100.00% ✓ $361.5K
Nov 17, 2017 Nov 21, 2017 Editas Medicine, Inc. CFO Sell 7.5 -10,000 -100.00% ✓ $250.8K
Feb 15, 2017 Feb 16, 2017 Editas Medicine, Inc. CFO Sell 10.0 -3,000 -100.00% ✓ $57.6K
Jan 11, 2017 Jan 13, 2017 Editas Medicine, Inc. CFO Sell 7.5 -15,000 -100.00% ✓ $288K